Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 293

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 293
---
 September17, 2009. DiamiR is a molecular diagnostics company focused on developing and commercializing minimally invasive tests for early detection and monitoring of neurodegenerative diseases, such as mild cognitive impairment and Alzheimer’s disease, rare neurodevelopmental diseases, such as Rett syndrome, other brain health disorders, and cancer. The proprietary platform technology developed at DiamiR and protected by over 50 issued patents is based on quantitative analysis of organ -enrichedmicroRNAs detectable in blood plasma. In addition to blood -basedmicroRNA panels, as part of its biopharma services DiamiR‘s CLIA/CAP -certifiedlaboratory offers protein and genetic biomarker analyses for screening, patient stratification, disease and treatment monitoring. Factors Affecting our Results of Operations Research and Development Expenses We believe our ability to successfully develop innovative drug candidates will be the primary factor affecting our long -termcompetitiveness, as well as our future growth and development. Creating high quality global first -in-classor best -in-classdrug candidates requires significant investment of resources over a prolonged period of time. As a result of this commitment, our pipeline of drug candidates has been steadily advancing. Our drug candidates are still in development, and we have incurred and will continue to incur significant research and development costs for pre -clinicalstudies and clinical trials. We expect that our research and development expenses may significantly increase in future periods in line with the advancement and expansion of the development of our drug candidates. 154

We have been able to fund the research and development expenses for our drug candidates through a range of sources, including the proceeds raised from our public offering and follow -onofferings on Nasdaq, private placement to other investors and line of credit facilities from shareholders, related parties and banks. This diversified approach to funding allows us to not depend on any one method of funding for our research and development activities, thereby reducing the risk that sufficient financing will be unavailable as we continue to accelerate the development of our drug candidates. Research and development expenses include: •employee and consultant compensation related expenses, including salaries, benefits and share based compensation expenses; •expenses incurred for payments to CROs, investigators and clinical trial sites that conduct our clinical studies; •the cost of acquiring IP rights which did not meet the criteria of capitalization under the U.S. GAAP; •cost associated with sponsored research programs with various universities and research institutions •facilities, depreciation, and other expenses, which include office leases and other overhead expenses; and